FLORHAM PARK, N.J. — December 22, 2025 — Leads & Copy — Celularity Inc. (Nasdaq: CELU) announced the closing of its financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP. Celularity received $10.00 million in gross proceeds at closing. The transaction structure allows for up to an additional $2.0 million, pending specific closing conditions and the investor’s decision.
The financing includes a senior secured term loan and a secured convertible note, intended to support Celularity’s operations and strategic initiatives.
The senior secured term loan has a principal amount of $7.0 million, secured by a first-priority lien on substantially all of Celularity’s assets, subject to exclusions and priority agreements. The secured convertible notes provide for commitments of up to $5.0 million, issuable in tranches, convertible into Celularity’s Class A common stock at $1.66 per share, subject to adjustment. These notes are secured by a first-priority lien on proceeds from a qualified financing.
Celularity also issued five-year warrants to purchase 3,707,657 shares of Class A Common Stock to the investor, exercisable from June 19, 2026, at an exercise price of $2.00 per share, subject to adjustment.
Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer of Celularity, stated that the closing strengthens Celularity’s financial position and provides flexibility to analyze and prioritize its platform and pipeline. He also expressed appreciation for Phil Barach’s support and confidence in Celularity.
Celularity is focused on leveraging its placental-derived platform to address unmet medical needs related to healthy aging and performance optimization and believes its technologies allow it to participate in the longevity landscape while managing its existing portfolio.
Dr. Hariri added that Celularity intends to articulate its corporate strategy in the new year, including aligning scientific capabilities with long-term opportunities in longevity and age-related disease. The objective is to reshape Celularity into a disciplined organization that can translate innovation into value for patients and shareholders.
The securities were sold in a private placement exempt from the Securities Act of 1933 and have not been registered under the Act or state securities laws. They may not be offered or sold in the United States without registration or an applicable exemption. Celularity has agreed to file registration statements with the SEC covering the resale of Class A common stock underlying the convertible notes and warrants sold in the private placement.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.
Celularity Inc. (Nasdaq: CELU) is a regenerative and aging-related cellular medicine company developing, manufacturing, and commercializing advanced biomaterial products and allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity aims to develop therapeutic solutions that address unmet global needs for therapies targeting aging mechanisms like cellular senescence, age-related chronic inflammation, and tissue degeneration.
Carlos Ramirez, Senior Vice President, Celularity Inc., can be reached at Carlos.ramirez@celularity.com.
Source: Celularity Inc.
